Trial · NCT00287469
Results by group76
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 76
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | 20mcg Recombinant HEV | Jaundice; IgM ≥ 100 WR U/mL | 0.0 | 95% Confidence Interval 0.0 to 0.4 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | Placebo | Jaundice; IgM ≥ 100 WR U/mL | 6.9 | 95% Confidence Interval 5.3 to 8.8 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | 20mcg Recombinant HEV | Jaundice; total lg ≥ 2500 WR U/mL | 0.3 | 95% Confidence Interval 0.1 to 1.0 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | Placebo | Jaundice; total lg ≥ 2500 WR U/mL | 0.1 | 95% Confidence Interval 0.0 to 0.6 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | 20mcg Recombinant HEV | Jaundice; IgM≥100 WR U/mL or total lg≥2500 WR U/mL | 0.3 | 95% Confidence Interval 0.1 to 1.0 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | Placebo | Jaundice; IgM≥100 WR U/mL or total lg≥2500 WR U/mL | 7.0 | 95% Confidence Interval 5.4 to 8.9 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | 20mcg Recombinant HEV | Illness; IgM ≥ 100 WR U/mL | 0.0 | 95% Confidence Interval 0.0 to 0.4 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | Placebo | Illness; IgM ≥ 100 WR U/mL | 0.3 | 95% Confidence Interval 0.1 to 1.0 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | 20mcg Recombinant HEV | Illness; total lg ≥ 2500 WR U/mL | 0.0 | 95% Confidence Interval 0.0 to 0.4 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | Placebo | Illness; total lg ≥ 2500 WR U/mL | 0.0 | 95% Confidence Interval 0.0 to 0.4 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | 20mcg Recombinant HEV | Illness; IgM≥100 WR U/mL or total lg≥2500 WR U/mL | 0.0 | 95% Confidence Interval 0.0 to 0.4 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | Placebo | Illness; IgM≥100 WR U/mL or total lg≥2500 WR U/mL | 0.3 | 95% Confidence Interval 0.1 to 1.0 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | 20mcg Recombinant HEV | Jaun/Ill; IgM≥100 WR U/mL or total lg≥2500 WR U/mL | 0.3 | 95% Confidence Interval 0.1 to 1.0 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period | Placebo | Jaun/Ill; IgM≥100 WR U/mL or total lg≥2500 WR U/mL | 7.4 | 95% Confidence Interval 5.7 to 9.3 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E Disease by Category During the Follow-up Period | 20mcg Recombinant HEV | Jaundice; IgM ≥ 100 WR U/ml | 0.1 | 95% Confidence Interval 0.0 to 0.6 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E Disease by Category During the Follow-up Period | Placebo | Jaundice; IgM ≥ 100 WR U/ml | 0.8 | 95% Confidence Interval 0.4 to 1.6 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E Disease by Category During the Follow-up Period | 20mcg Recombinant HEV | Jaundice; total Ig ≥ 2500 WR U/ml | 0.0 | 95% Confidence Interval 0.0 to 0.4 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E Disease by Category During the Follow-up Period | Placebo | Jaundice; total Ig ≥ 2500 WR U/ml | 0.0 | 95% Confidence Interval 0.0 to 0.4 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E Disease by Category During the Follow-up Period | 20mcg Recombinant HEV | Jaundice; IgM≥100 WR U/mL or total lg≥2500 WR U/mL | 0.1 | 95% Confidence Interval 0.0 to 0.6 | Percent of Participants |
| Percent of Participants of Definite Hepatitis E Disease by Category During the Follow-up Period | Placebo | Jaundice; IgM≥100 WR U/mL or total lg≥2500 WR U/mL | 0.8 | 95% Confidence Interval 0.4 to 1.6 | Percent of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00287469/results